NCT04151329 - A Phase I Clinical Trial of BAT1306 and BAT8001 Injection in Patients With Solid Tumor | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

June 21, 2019

Primary Completion Date

December 31, 2020

Study Completion Date

June 30, 2021

Conditions

Solid Tumor

Interventions

BIOLOGICAL

BAT1306 and BAT8001 2.4mg/kg

Phase 1 dose titration study of BAT1306 and BAT8001 2.4mg/kg , then choose a proper dose for amplification study based on DLT result

BIOLOGICAL

BAT1306 and BAT8001 3.6mg/kg

Phase 1 dose titration study of BAT1306 and BAT8001 3.6mg/kg , then choose a proper dose for amplification study based on DLT result

Trial Locations (1)

Medical Ethics Committee of Shanghai East Hospital, Shanghai